Cipla Q3 net up 25.5 percent, slightly misses estimates
MUMBAI (Reuters) - Cipla Ltd (CIPL.NS), India's fifth largest drugmaker by sales, reported a 25.5 percent rise in quarterly profit on robust sales but slightly missed street estimates as taxes surged.
The Mumbai-based drugmaker said, net profit grew to 3.39 billion rupees in October-December from 2.7 billion rupees a year earlier. Analysts on an average had expected a net profit of 3.48 billion rupees, according to Thomson Reuters I/B/E/S.
Sales rose 18.65 percent to 20.3 billion rupees, it said.
Shares in Cipla fell 0.56 percent to 405 rupees on Wednesday when the Mumbai market closed down 0.1 percent. (Reporting by Kaustubh Kulkarni; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- Boxer Sarita Devi faces action after refusing medal at Asian Games
- Brookfield wins Revel Casino auction, but loser vows to fight
- CANADA STOCKS-TSX fall gets deeper as financial, energy shares drag
- UPDATE 2-EU-Russia gas duel deepens with Slovakia supply cut
- Billionaire Detroit business leader says "blight is like a cancer"
India could run out of a critical medicine in its free HIV/AIDS drugs programme in three weeks due to bureaucratic bungling, a senior government official said, leaving more than 150,000 sufferers without life-saving drugs for about a month. Full Article